Chimeric antigen receptor T-cell therapy is superior to standard of care as second-line therapy for large B-cell lymphoma: A systematic review and meta-analysis.

"CONFLICT OF INTEREST Liat Shargian–Advisory board and honoraria payment from Gilead and Novartis. Anat Gafter‐Gvili–Honoraria payment from Novartis. Ronit Gurion–Advisory board and honoraria payment from Gilead and Novartis."

"Primary outcomes included both EFS and overall survival (OS). Secondary outcomes included ORR, CR rate, progression‐free survival (PFS) and safety. OS was defined as the time from randomisation to death from any cause. EFS in the included trials was defined as: time from randomisation to death from any cause, progressive disease (PD), failure to achieve CR or PR by 9 weeks (TRANSFORM; ClinicalTrials.gov Identifier: NCT03575351) or day 150 (21 weeks) [ZUMA‐7; ClinicalTrials.gov Identifier: NCT03391466) after randomisation, or start of new anti‐neoplastic therapy, whichever occurred first. The BELINDA trial (ClinicalTrials.gov Identifier: NCT03570892) defined EFS as the time from randomisation to stable disease (SD) or PD at or after the week 12 assessment or death at any time. Response assessment was conducted in all trials by independent review committee according to the Lugano criteria. Dates of initial response assessment varied; TRANSFORM – weeks 9 and 18, ZUMA‐7 – day 50 and 100 and BELINDA – weeks 6 and 12."